Rockwell Medical (RMTI) Projected to Release Quarterly Earnings on Thursday

Rockwell Medical (NASDAQ:RMTI) is expected to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.1812) per share and revenue of $18.22 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.10). The firm had revenue of $17.78 million for the quarter, compared to analyst estimates of $17.82 million. Rockwell Medical had a negative return on equity of 14.03% and a negative net margin of 7.33%. On average, analysts expect Rockwell Medical to post ($0.90) EPS for the current fiscal year and $0.36 EPS for the next fiscal year.

Rockwell Medical Stock Performance

Rockwell Medical stock opened at $7.52 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.25 and a quick ratio of 3.00. Rockwell Medical has a fifty-two week low of $4.89 and a fifty-two week high of $12.90. The stock’s fifty day moving average is $7.87 and its two-hundred day moving average is $8.16.

Analysts Set New Price Targets

RMTI has been the subject of several research reports. Zacks Research downgraded Rockwell Medical from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Wall Street Zen raised shares of Rockwell Medical to a “hold” rating in a research note on Saturday, July 25th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Rockwell Medical in a research note on Friday, September 11th. Finally, Weiss Ratings upgraded shares of Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $20.00.

About Rockwell Medical

Rockwell Medical, Inc is a healthcare company focused on developing, manufacturing and commercializing products used in the treatment of patients with end-stage renal disease (ESRD) who receive hemodialysis. The company supplies products intended to support anemia management and other aspects of dialysis care.

Its principal pharmaceutical product is Triferic, an iron replacement therapy designed to deliver iron to hemodialysis patients through the dialysate. Rockwell Medical also markets Triferic AVNU, an intravenous formulation administered during hemodialysis.